Oppenheimer Lifts Pharvaris Target to $75 After Oral HAE Pill Cuts Attacks by 83%
Oral deucrictibant XR met all endpoints; FDA filing eyed for H1 2027.
/ 2 items
Oral deucrictibant XR met all endpoints; FDA filing eyed for H1 2027.
BofA upgrades Pharvaris to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data.